BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 27418196)

  • 1. Loss of YAP1 defines neuroendocrine differentiation of lung tumors.
    Ito T; Matsubara D; Tanaka I; Makiya K; Tanei ZI; Kumagai Y; Shiu SJ; Nakaoka HJ; Ishikawa S; Isagawa T; Morikawa T; Shinozaki-Ushiku A; Goto Y; Nakano T; Tsuchiya T; Tsubochi H; Komura D; Aburatani H; Dobashi Y; Nakajima J; Endo S; Fukayama M; Sekido Y; Niki T; Murakami Y
    Cancer Sci; 2016 Oct; 107(10):1527-1538. PubMed ID: 27418196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP1 promotes multidrug resistance of small cell lung cancer by CD74-related signaling pathways.
    Song Y; Sun Y; Lei Y; Yang K; Tang R
    Cancer Med; 2020 Jan; 9(1):259-268. PubMed ID: 31692299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
    Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
    Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
    Kawai H; Matsuoka R; Ito T; Matsubara D
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
    Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
    Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
    Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
    Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.
    Kalari S; Jung M; Kernstine KH; Takahashi T; Pfeifer GP
    Oncogene; 2013 Jul; 32(30):3559-68. PubMed ID: 22907430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High grade neuroendocrine lung tumors: pathological characteristics, surgical management and prognostic implications.
    Grand B; Cazes A; Mordant P; Foucault C; Dujon A; Guillevin EF; Barthes FLP; Riquet M
    Lung Cancer; 2013 Sep; 81(3):404-409. PubMed ID: 23769675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.
    Cheng H; Zhang Z; Rodriguez-Barrueco R; Borczuk A; Liu H; Yu J; Silva JM; Cheng SK; Perez-Soler R; Halmos B
    Oncotarget; 2016 May; 7(20):28976-88. PubMed ID: 26716514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
    Schnabel PA; Junker K
    Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic modifications of histone h4 in lung neuroendocrine tumors.
    Li F; Ye B; Hong L; Xu H; Fishbein MC
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):389-94. PubMed ID: 21415707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.
    Pearsall SM; Humphrey S; Revill M; Morgan D; Frese KK; Galvin M; Kerr A; Carter M; Priest L; Blackhall F; Simpson KL; Dive C
    J Thorac Oncol; 2020 Dec; 15(12):1836-1843. PubMed ID: 32721553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.
    Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC
    Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
    Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
    Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of YAP1 in small cell lung cancer.
    Saito H; Tenjin Y; Yamada T; Kudoh S; Kudo N; Sanada M; Sato Y; Matsuo A; Orita Y; Ito T
    Hum Cell; 2022 Mar; 35(2):628-638. PubMed ID: 35072899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.
    Jones MH; Virtanen C; Honjoh D; Miyoshi T; Satoh Y; Okumura S; Nakagawa K; Nomura H; Ishikawa Y
    Lancet; 2004 Mar; 363(9411):775-81. PubMed ID: 15016488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes.
    Lorenzetto E; Brenca M; Boeri M; Verri C; Piccinin E; Gasparini P; Facchinetti F; Rossi S; Salvatore G; Massimino M; Sozzi G; Maestro R; Modena P
    Oncotarget; 2014 May; 5(9):2608-21. PubMed ID: 24810989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
    Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
    Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype.
    Vos MD; Scott FM; Iwai N; Treston AM
    J Cell Biochem Suppl; 1996; 24():257-68. PubMed ID: 8806108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.